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Background: Angiogenic gene therapy has been demonstrated to enhance
perfusion to ischemic tissues, but it is unknown whether the administra-
tion of angiogenic growth factors will increase blood flow to nonischemic
tissues. This study investigates whether enhanced myocardial perfusion
can be mediated by adenovirus-mediated transfer of vascular endothelial
growth factor 121 cDNA to nonischemic myocardium.
Methods: New Zealand White rabbits received adenovirus (5  1010
particle units) encoding for vascular endothelial growth factor 121 (n 
14) or a control vector without a transgene (n  13) or saline solution (n
 9) via direct myocardial injection. Fluorescent microsphere perfusion studies and
histologic analyses were performed 4 weeks later. In a parallel study, exercise
treadmill testing was performed to assess the functional effects of this therapy in
Sprague-Dawley rats.
Results: Microsphere assessment of myocardial perfusion in rabbits 4 weeks after
adenovirus-encoding vascular endothelial growth factor administration was greater
than that for rats injected with control vector without a transgene or saline solution
(3.2  0.5 vs 2.7  0.7 and 2.4  0.4, respectively; P  .03). The endothelial cell
count per high power field was increased in animals injected with adenovirus-
encoding vascular endothelial growth factor versus animals injected with control
vector without a transgene or saline solution (147  27 vs 123  14 and 125  16
cells, respectively), although this did not reach statistical significance (P  .12).
Rats treated with adenovirus-encoding vascular endothelial growth factor also
demonstrated prolonged exercise tolerance compared with rats injected with control
vector without a transgene or saline solution (exhaustion time: 26  5 minutes vs
19  2 minutes and 20  3 minutes, respectively; P  .006).
Conclusions: Adenovirus encoding–mediated transfer of vascular endothelial
growth factor 121 induces an enhancement in regional perfusion in nonischemic
myocardium that corresponds to changes in exercise tolerance. Adenovirus-encod-
ing vascular endothelial growth factor therapy may be useful for inducing angio-
genesis in the nonischemic state, such as for prophylactic therapy of early coronary
artery disease.
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The administration of growth factors has beendemonstrated to enhance blood vesselgrowth and perfusion to ischemic tissues in anumber of models.1-5 It has been postulatedthat such “therapeutic angiogenesis” will notoccur in nonischemic tissues because of an
absence of adequate growth factor receptor up-regulation in
these tissues.6-9 This hypothesis has in part served as the
rationale for systemic delivery of angiogenic agents, assum-
ing that potentially deleterious angiogenesis will not occur
in “normal” tissues but only in ischemic tissues possessing
an appropriate level of receptor up-regulation.7-9
Contrary to these suppositions, growth factor adminis-
tration has been demonstrated to enhance tissue vascular-
ization in several nonischemic models.10-15 Growth factors
have also been successfully administered as a prophylactic
therapy prior to vascular ligation.13-15 It is likely that this
observed induction of angiogenesis in nonischemic tissues
is made possible in part by the ability of growth factors to
up-regulate the expression of their own receptor; for exam-
ple, as in the case of vascular endothelial growth factor
(VEGF) up-regulation of flk-1.16
It has not been previously determined whether the ad-
ministration of angiogenic growth factors will cause a phys-
iologically significant increase in perfusion to nonischemic
tissues, as opposed to only increasing blood vessel number.
Theoretically, such enhanced perfusion might result in im-
proved functional capabilities of these tissues. Importantly,
such findings would refute the existing presumption that
up-regulation of receptor expression in ischemic tissues will
limit angiogenic effects to these tissues following systemic
growth factor administration. This study consequently in-
vestigates the effects of adenoviral-mediated transfer of
VEGF121 cDNA to nonischemic myocardium and demon-
strates enhanced myocardial perfusion and improved exer-
cise tolerance in this setting.
Materials and Methods
Ad Vectors
The replication-defective vector AdVEGF is an E1a, partial
E1b, partial E3 adenovirus (Ad) vector based on human Ad
serotype 5, with the expression cassette inserted in the E1 region
in the right-to-left orientation. The expression cassette includes the
cytomegalovirus immediate early promoter/enhancer, an artificial
splice sequence, the human VEGF121 cDNA, and the simian virus
40 poly(A)/stop signal.17 As a negative control, a similar adeno-
virus (AdNull) containing no gene in the expression cassette was
used. All Ad vectors were propagated, purified, and quantitated as
previously described, and all replication-defective vector prepara-
tions were demonstrated to be free of replication-competent ade-
novirus.17 VEGF protein expression by AdVEGF was confirmed
by enzyme-linked immunosorbent assay (R&D Systems, Minne-
apolis, Minn), with 500 ng VEGF detected per 1  1011 particle
units (pu) of AdVEGF assayed in culture.
Perfusion Studies (Rabbit)
Male New Zealand White rabbits (average weight 3 kg; Covance
Research Products, Denver, Pa) were treated in accordance with
institutional animal care and use committee (IACUC) guidelines.
The rabbits were sedated with subcutaneous ketamine (35 mg/kg)
and xylazine (2 mg/kg). Following endotracheal intubation, gen-
eral anesthesia was maintained with 3 L O2 and intravenous
fentanyl (150 g/kg). A left lateral thoracotomy was then per-
formed, and 5  1010 pu of AdVEGF (n  14), AdNull (n  13),
or saline solution (n  9) was delivered via direct myocardial
injection using a 27G tuberculin syringe at 4 sites on the anterior
and posterior left ventricular walls at the midventricular level (25
L per injection), encompassing the left ventricular free wall.
Four weeks later, a repeat thoracotomy was performed and 2
106 fluorescent 15-m microspheres (Molecular Probes, Eugene,
Ore) were injected via left atrial cannulation. After killing the
animals under general endotracheal anesthesia, the left ventricle
was sectioned into upper, middle, and apical thirds. The upper and
middle sections (rings) were divided into septal, anterior, and
posterior segments, while the apical section was preserved as 1
segment. Spheres were liberated from these segments by alkali
digestion and quantified in a blinded fashion, as previously de-
scribed.18 An index of perfusion was calculated as the ratio of the
microspheres per gram of tissue extracted from each ventricular
segment divided by the number of microspheres per gram of tissue
extracted from the (untreated) upper septum, which served as an
internal reference. A composite upper and lower ventricular per-
fusion index was calculated as the sum of the perfusion indices of
the treated upper and middle rings, respectively.
Histologic Evaluation (Rabbit)
Three additional groups of rabbits underwent the administration of
AdVEGF (n  9), AdNull (n  8), or saline solution (n  7) as
described above. Four weeks later, the animals were killed after a
pentobarbital overdose (150 mg/kg IV), the hearts were prepared
for histologic analysis in 10% neutral buffered formalin, embedded
in paraffin, and sectioned. Endothelial cells were stained for 1 hour
with a 1:100 dilution of biotinylated Griffonia simplicifolia lectin
(Vector Labs, Burlingame, Calif). Stained regions were visualized
using an avidin-biotin-peroxidase complex and diaminobenzidine
substrate, as previously described. The mean endothelial cell count
was calculated in a blinded fashion from the number of endothelial
cells seen in 3 randomly selected high-power fields from these
sections of the injected regions of the left ventricle and the (unin-
jected) upper and lower septum.
Exercise Protocol (Rat)
Male Sprague-Dawley rats (average weight 360 g; Harlan, India-
napolis, Ind) were treated in accordance with IACUC guidelines.
Rats were administered five injections (20 L) of AdVEGF or
AdNull (1  1010 pu) or saline solution (n  8 per group) in a
manner analogous to that for the rabbit studies. Prior to injection,
all animals were trained for 10 minutes on a multitrack small
animal motorized treadmill (Model 42-15, Quinton, Bothell,
Wash) at a constant speed of 15 m/min. Two weeks after surgery,
the rats were exercised on the same treadmill according to a
standardized protocol, as follows: 10 m/min for 5 minutes, 15
m/min for 5 minutes, and 25 m/min for the remainder of the
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experiment.19 Exhaustion was defined as the time point at which
the animals rats sustained 10 falls per minute onto the electrified
grid at the end of each running track.19
Statistical Analysis
Data are expressed as means and standard deviations. Analysis of




A composite myocardial perfusion index was calculated
from microsphere harvests from nonischemic rabbits 4
weeks following the administration of AdVEGF, AdNull, or
saline solution (Figure 1). The composite index for the
lower ventricle was significantly greater (P  .03) 4 weeks
after AdVEGF administration (3.2  0.5) compared with
the composite index 4 weeks after the administration of
AdNull (2.7  0.7) or saline solution (2.4  0.4). In
comparison, perfusion to the upper ventricular segments
was not significantly different between groups (P  .6),
consistent with the pattern of injections and the cephalad to
caudad course of coronary flow.
A trend toward enhanced perfusion to the noninjected
lower septum was also demonstrated in animals treated with
AdVEGF versus animals treated with AdNull or saline
solution (lower septum perfusion index: AdVEGF, 0.94 
0.17; AdNull, 0.81  0.22; saline solution, 0.79  0.14;
P  .095). Increased perfusion of the septum through per-
forating branches of the left anterior descending coronary
artery, which courses through the area of injection, may in
part explain this finding.
Rabbit Myocardial Histology
Mean endothelial cell number per microscopic field in the
injected anterior and posterior midventricular segments was
increased in animals injected with AdVEGF versus AdNull
or saline solution (147  27 vs 123  14 and 125  16
cells, respectively), although this did not reach statistical
significance (P  .12; Figure 2, A). Consistent with the
expectation of localized spread of the Ad vector beyond the
Figure 1. Microsphere perfusion to the lower ventricle of rabbits
4 weeks following treatment. Results for each animal and mean
 standard deviation are shown.
Figure 2. Histologic assessment of rabbit myocardium following
treatment. A, Quantification of endothelial cell number per high
power field in treatment groups, as indicated (mean  standard
deviation). *P .12. B, Left panel: Lectin stain of a VEGF injection
site shows endothelial cells in brown (400); right panel: lectin
stain of a control heart (injected with saline solution) shows
almost no endothelial cell staining (400). C, Lectin stain of a
VEGF-injected heart adjacent to injection site shows vascular
channels infiltrating the myocardium (200).
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area immediately surrounding the injection site, endothelial
cell number in the noninjected lower septum also demon-
strated a trend toward increased values in animals injected
with AdVEGF versus AdNull or saline solution (156  28
vs 112  26 and 114  18 cells, respectively; P  .13).
Qualitative analysis of treated territories is remarkable for
the lack of inflammation or infarction noted in these tissues
(Figure 2, B, C). Histologic analysis in AdVEGF-treated
animals furthermore suggests a predominant pattern of
small-vessel development.
Rat Exercise Tolerance
AdVEGF-treated rats demonstrated significantly prolonged
exercise tolerance (P  .006) 2 weeks postinjection (aver-
age time to exhaustion: 26  5 minutes) compared with
animals treated with AdNull (19  2 minutes) or saline
solution (20  3 minutes; Figure 3).
Discussion
The present study demonstrates an increase in perfusion in
nonischemic myocardial tissue and an improvement in ex-
ercise tolerance following the administration of vascular
endothelial growth factor by means of an adenovirus vector.
These findings are consistent with the ability of VEGF and
other growth factors to mediate the up-regulation of their
own receptors,16 although these studies do not prove a
causal relationship in this regard. Importantly, these data
refute the existing assumption that potentially deleterious
angiogenesis will not occur in sensitive tissues such as the
retina or in occult tumors in the absence of ischemic up-
regulation of angiogenic receptors, an assumption which
has served as the rationale for systemic administration of
angiogenic growth factors in some clinical trials.7-9
Although it cannot be ruled out that some degree of
ischemia induced by surgical manipulation or other stresses
did not play a role in enhancing perfusion in this study, the
significantly greater changes in perfusion and exercise tol-
erance observed in the VEGF compared with the non-VEGF
control groups suggest that this is not the case. Although it
would be useful to determine whether substantial degrees of
ischemia would have created an even greater enhancement
of perfusion than that observed in this nonischemic model,
the presence of different baseline levels of perfusion in
ischemic versus nonischemic hearts unfortunately precludes
a meaningful comparison of this parameter. Further, given
the relatively high levels of perfusion in the nonischemic
myocardium, it is not unexpected that the increases in
perfusion noted in this study were only modest.
The observed increase in endothelial cell number in the
present study, although not statistically significant, is con-
sistent with improvements seen in previously reported re-
sults for nonischemic tissues.1,13,14 It is difficult to account
for the relative discrepancy between the modest increase in
endothelial cell number and relatively greater increases in
physiologic parameters noted in these and other studies in
ischemic models.1-6 Conceivably, these differences may be
related in some way to the artifact of the “two-dimension-
ality” of histologic analyses (ie, many cells out of the
microscopic plane are not visualized) and the potentially
nonlinear relationship between new vasculature and the
perfusion and enhancement of function potentially provided
by these vessels.
It is interesting to note that endothelial cell number and
perfusion to the ventricular septum were increased in the
present study, despite the limiting of injections to the left
ventricular free wall. This finding is consistent with a pat-
tern of global improvement in ventricular function we have
noted following direct myocardial injection of AdVEGF to
the left ventricular free wall in a pacing model of cardio-
Figure 3. Time to exhaustion (mean  standard deviation) for rat treadmill testing 2 weeks following various
treatment regimens, as described in Methods. *P < .006.
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myopathy20 and our prior observations of only partial lo-
calization of transgene expression following intramyocar-
dial delivery.21-23 Localized angiogenic effects in treated
areas may result in enhanced perfusion to neighboring ter-
ritories through collateral flow, such as the septal branches
of the left anterior descending, which in turn is situated in a
treated myocardial territory. Alternatively, the septal tissue
may be exposed to AdVEGF through the local diffusion of
the aqueous vector solution through the myocardium or
through transmyocardial vascular transport.
Data in the present study suggest but do not prove the
likelihood of long-term persistence of the noted perfusion
changes, nor do they prove a prophylactic capability for this
therapy in preventing or minimizing myocardial infarction
in the setting of a subsequent vascular occlusion. Given the
fact that adenoviral-mediated VEGF expression is largely
extinguished by 1 week after vector administration,12,21-23
however, the presence of increased perfusion at 4 weeks
after vector administration suggests that these changes per-
sist at least beyond the duration of VEGF expression. Our
prior observations of neovasculature persistence at 90 days
following AdVEGF administration in the rat fat pad and
findings of a prophylactic effect in peripheral and myocar-
dial ischemia models after vector administration12-15 simi-
larly suggest that persistence of perfusion changes is possi-
ble, as do our recent findings in a prophylactic peripheral
model 6 weeks after vector administration (unpublished
data). It has been suggested that the administration of an-
giogenic cofactors such as angiopoietin-1 or platelet-de-
rived growth factor might further stabilize and allow the
persistence of a neovasculature.24,25 Alternatively, the pres-
ence of flow through newly created vessels might create
sufficient impetus for persistence without such additional
therapy. The findings of this study suggest that angiogenic
therapy may be of benefit in treating tissues not traditionally
considered to be ischemic, such as those neighboring an
ischemic myocardial segment in patients with coronary
artery disease, or in nonatherosclerotic conditions, such as
ventricular hypertrophy or enlargement in the setting of
valvular disease. These findings also suggest the possibility
of creating tissues that may function in “hypernormal”
modes; for example, when accelerated wound healing is
required. Finally, given evidence of correlations between
treadmill aerobic running capacity and left ventricular func-
tion in isolated heart preparations,26,27 the enhancement of
exercise tolerance noted in the AdVEGF-treated “normal”
animals may indicate that myocardial perfusion may be a
limiting component in cardiac performance. We are aware
that such treatment holds implications for improving ath-
letic performance.
We thank B. Cushing for help in preparation of this manuscript.
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